Helix BioPharma Corp. saw a slight uptick in stock performance this week, despite ongoing challenges in the capital markets.
Helix BioPharma Corp. (HBP.TO), a company focused on developing innovative therapies in oncology, has experienced a modest rise in its stock price this week. As of the latest trading session, the stock closed at C$1.40, reflecting a 2.86% increase over the past week. However, the stock remains significantly lower year-to-date, down 40%.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeMarket cap
$114.57M
52W high
$5.40
52W low
$0.98
1W change
+2.07%
Beta
-0.35
Analyst Price Targets
Based on analyst covering HBP
Wall Street analysts forecast HBP stock price to rise 68.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+68.9% Upside
Current Price
C$1.48
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
48.7%
Annualized
90-Day Vol
65.6%
Annualized
Trend (90d)
-43.1%
Annualized drift
90d Mean
C$1.27
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.41 | C$1.19 – C$1.66 |
| 60 trading days | C$1.34 | C$1.05 – C$1.69 |
| 90 trading days | C$1.27 | C$0.95 – C$1.70 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should note that while Helix BioPharma has made strides in its oncology programs, the company continues to face challenges, including recent capital market conditions and negative financial indicators. It's essential for investors to stay informed about the company's developments and financial health.
C$1.40 Close with 2.86% Weekly Gain
The stock has traded within a 52-week range of C$0.95 to C$5.40, indicating significant volatility and investor uncertainty.
Bull case
Analysts have a positive outlook for Helix BioPharma, with an average target price of C$2.50. This suggests that there could be potential gains for investors if the company can successfully navigate its current challenges and advance its oncology initiatives.
Bear case
Despite the optimistic analyst outlook, Helix BioPharma's financials raise concerns. The company has a profit margin of 0.0% and a return on equity of -50.0%, indicating that it may struggle to achieve profitability in the near term.
Price Action Overview
Advertisement
Helix BioPharma Corp. closed at C$1.40, marking a 2.86% increase for the week. This performance is a slight recovery from the stock's year-to-date decline of 40%. Investors are keeping a close eye on the stock as it navigates through challenging market conditions.
Recent Company News
No significant company news has been reported this week. However, recent headlines include the filing of interim financial statements and the closing of a private placement, which raised CAD$3,000,000 for working capital. These developments indicate the company's efforts to secure necessary funding amid challenging capital markets.
Technical Picture
From a technical standpoint, Helix BioPharma's stock is trading below its 50-day moving average of C$1.58 and its 200-day moving average of C$2.00, indicating bearish sentiment. The stock has a beta of -0.35, suggesting it is less volatile than the broader market. Recent trading volume has been low, with only 308 shares traded compared to the 20-day average volume of 1,255 shares, reflecting decreased investor interest.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
